US Pharma MarketingNovo CEO cites pricing 'sweet spot' as Wegovy pill debuts with $355M quarter
After several consecutive quarters on the backfoot, Danish drug juggernaut Novo Nordisk is receiving warmer feedback on its starting performance in 2026, thanks in no small part to its head start o After several consecutive quarters on the backfoot, Danish drug juggernaut Novo Nordisk is receiving warmer feedback on its starting performance in 2026, thanks in no small part to its head start over rival Eli Lilly in the burgeoning market for oral obesity therapies. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala…
After several consecutive quarters on the backfoot, Danish drug juggernaut Novo Nordisk is receiving warmer feedback on its starting performance in 2026, thanks in no small part to its head start over rival Eli Lilly in the burgeoning market for oral obesity therapies.
Source: FiercePharma